Literature DB >> 27348392

Revision Surgery for Superior Canal Dehiscence Syndrome.

Jeffrey D Sharon1, Seth E Pross, Bryan K Ward, John P Carey.   

Abstract

OBJECTIVE: To identify factors associated with surgical failure for superior canal dehiscence syndrome (SCDS) and define rates of complications and cure after revision SCDS repair. STUDY
DESIGN: Retrospective patient series.
SETTING: Tertiary care referral center. PATIENTS: Adults who underwent revision surgery for SCDS.
INTERVENTIONS: None. MAIN OUTCOME MEASURES: Initial surgical approach, intraoperative findings at the time of revision, persistence of symptoms, and complications for revision surgery.
RESULTS: Two hundred twenty-two surgical SCDS patients were identified, including 21 subjects who underwent 23 revision surgeries. Fourteen (61%) underwent previous middle fossa and nine (39%) underwent previous transmastoid approaches. Intraoperative findings showed that in 17 (74%) the previous material used to plug or resurface the canal was present but not entirely covering the dehiscence. In one (4%) the material was not present. In one (4%) the material was in proper position, whereas in four (17%) the material was in proper position with very thin bone adjacent. After revision surgery, symptoms were completely resolved in eight (35%), partially resolved in seven (30%), and not resolved in seven (30%). Findings of thin bone adjacent to the previous plug was associated with failure of symptom resolution (p = 0.03). Hearing outcomes were compared to a previously studied cohort of primary surgery patients, and outcomes were similar. Three subjects (13%) had a significant decrease in their word recognition score after revision surgery (p=0.52), and seven (30%) had a significant increase in their pure-tone average (p=0.78).
CONCLUSION: Revision surgery for SCDS can be curative in carefully selected patients, but there may be a higher failure rate than primary surgery, with similar hearing outcomes.

Entities:  

Mesh:

Year:  2016        PMID: 27348392     DOI: 10.1097/MAO.0000000000001113

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  7 in total

1.  Clinical and Physiologic Predictors and Postoperative Outcomes of Near Dehiscence Syndrome.

Authors:  Michael Baxter; Colin McCorkle; Carolina Trevino Guajardo; Maria Geraldine Zuniga; Alex M Carter; Charles C Della Santina; Lloyd B Minor; John P Carey; Bryan K Ward
Journal:  Otol Neurotol       Date:  2019-02       Impact factor: 2.311

2.  Comorbidities confounding the outcomes of surgery for third window syndrome: Outlier analysis.

Authors:  P Ashley Wackym; Heather T Mackay-Promitas; Shaban Demirel; Gerard J Gianoli; Martin S Gizzi; Dale M Carter; David A Siker
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-08-22

3.  Description of a New Labyrinthine Dehiscence: Horizontal Semicircular Canal Dehiscence at the Tympanic Segment of the Facial Nerve.

Authors:  Gerard Gianoli; James Soileau; Bradley Shore
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

Review 4.  Recent surgical options for vestibular vertigo.

Authors:  Stefan Volkenstein; Stefan Dazert
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2017-12-18

Review 5.  Superior Canal Dehiscence Syndrome: Lessons from the First 20 Years.

Authors:  Bryan K Ward; John P Carey; Lloyd B Minor
Journal:  Front Neurol       Date:  2017-04-28       Impact factor: 4.003

6.  Third Window Syndrome: Surgical Management of Cochlea-Facial Nerve Dehiscence.

Authors:  P Ashley Wackym; Carey D Balaban; Pengfei Zhang; David A Siker; Jasdeep S Hundal
Journal:  Front Neurol       Date:  2019-12-13       Impact factor: 4.003

7.  Superior semicircular canal dehiscence syndrome: Diagnostic criteria consensus document of the committee for the classification of vestibular disorders of the Bárány Society.

Authors:  Bryan K Ward; Raymond van de Berg; Vincent van Rompaey; Alexandre Bisdorff; Timothy E Hullar; Miriam S Welgampola; John P Carey
Journal:  J Vestib Res       Date:  2021       Impact factor: 2.354

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.